Health ❯ Healthcare ❯ Pharmaceuticals ❯ Cancer Treatment

Breast Cancer

EMA Recommends Etcamah for ESR1‑Mutant Advanced Breast Cancer

Built on SERENA‑6 interim data showing a clear progression‑free survival gain, the CHMP opinion now sends the file to the European Commission for a final EU decision.

6 ARTICLES

3mo ago

Novartis Strikes $2 Billion Deal for Mutant-Selective PI3Kα Cancer Drug SNV4818

3 ARTICLES

6mo ago

Lilly’s Imlunestrant Data Show Stronger Results With Abemaciclib, Delayed Chemotherapy in ER+ Breast Cancer

9 ARTICLES

6mo ago

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial

4 ARTICLES

7mo ago

Olema Soars on Roche SERD Win, Then Slips on Planned Stock Offering

8 ARTICLES

8mo ago

Datroway Extends Survival Over Chemotherapy in First-Line TNBC Ineligible for Immunotherapy

8 ARTICLES

9mo ago

FDA Approves Lilly’s Inluriyo for ESR1‑Mutated Advanced Breast Cancer

3 ARTICLES

last yr.

FDA Expands Approval of Kisqali for Early-Stage Breast Cancer